Last reviewed · How we verify

NCT03423888: OXYPALL

High-flow Nasal Oxygen in Palliative Care: Pilot Study

Completed NA Last updated 14 April 2022
What this trial tests

NA trial testing high-flow nasal cannula oxygen therapy (HNFC) in Dyspnea in 30 participants. Completed in 25 January 2022.

Timeline
13 February 2018
Primary endpoint
25 January 2022
25 January 2022

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment30
Start date13 February 2018
Primary completion25 January 2022
Estimated completion25 January 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

18 and older, any sex, with Dyspnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In palliative care, the relief of the dyspnea is necessary. Medications for the reduction of dyspnea have side effects. High-flow nasal cannula oxygen therapy (HFNC) is a new way to deliver oxygen. Investigators hypothesize that HNFC is an acceptable technic for the patient with dyspnea in palliative care. A pilot study with 30 patients will be conducted. Acceptability of HNFC will be studied by the time of use by patients of the HNFC during one week. The effectiveness of HNFC in relieving dyspnea will be studied using Borg scale.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dyspnea

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03423888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing